183 related articles for article (PubMed ID: 38297237)
1. Laboratory and clinical features of tumor lysis syndrome in children with non-Hodgkin lymphoma and evaluation of long-term renal functions in survivors.
Bozkurt S; Genc DB; Vural S
BMC Pediatr; 2024 Jan; 24(1):85. PubMed ID: 38297237
[TBL] [Abstract][Full Text] [Related]
2. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
[TBL] [Abstract][Full Text] [Related]
3. Tumor lysis syndrome in children with non-Hodgkin lymphoma.
Alavi S; Arzanian MT; Abbasian MR; Ashena Z
Pediatr Hematol Oncol; 2006; 23(1):65-70. PubMed ID: 16326415
[TBL] [Abstract][Full Text] [Related]
4. The analysis of the risks for the development of tumour lysis syndrome in children.
Kopecna L; Dolezel Z; Osvaldova Z; Starha J; Hrstkova H
Bratisl Lek Listy; 2002; 103(6):206-9. PubMed ID: 12448566
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
6. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
7. Tumour lysis syndrome in children: experience of last decade.
Ahn YH; Kang HJ; Shin HY; Ahn HS; Choi Y; Kang HG
Hematol Oncol; 2011 Dec; 29(4):196-201. PubMed ID: 21710502
[TBL] [Abstract][Full Text] [Related]
8. Impaired renal function and tumor lysis syndrome in pediatric patients with non-Hodgkin's lymphoma and B-ALL. Observations from the BFM-trials.
Seidemann K; Meyer U; Jansen P; Yakisan E; Rieske K; Führer M; Kremens B; Schrappe M; Reiter A
Klin Padiatr; 1998; 210(4):279-84. PubMed ID: 9743966
[TBL] [Abstract][Full Text] [Related]
9. Fixed-Dose Recombinant Urate Oxidase in the Treatment of Paediatric Tumour Lysis Syndrome: A Regional Cancer Centre Experience.
L A; Reddy JM; Chebbi PG; Kumar N; Ar AK; M P; B S AK
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3897-3901. PubMed ID: 34967569
[TBL] [Abstract][Full Text] [Related]
10. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury in bortezomib-treated patients with multiple myeloma.
Song SM; Jeon J; Jang HR; Kim K; Huh W; Kim YG; Lee JE
Nephrol Dial Transplant; 2023 Aug; 38(9):2077-2085. PubMed ID: 36662030
[TBL] [Abstract][Full Text] [Related]
13. Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome.
Biró E; Erdélyi D; Varga P; Sinkó M; Bartyik K; Kovács G; Ottóffy G; Vincze F; Szegedi I; Kiss C; Szabó T
Pediatr Nephrol; 2023 Sep; 38(9):3117-3127. PubMed ID: 36943467
[TBL] [Abstract][Full Text] [Related]
14. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma.
Personett HA; Barreto EF; McCullough KB; Dierkhising R; Leung N; Habermann TM
Leuk Lymphoma; 2019 Sep; 60(9):2271-2277. PubMed ID: 31223041
[TBL] [Abstract][Full Text] [Related]
15. Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome.
Truong TH; Beyene J; Hitzler J; Abla O; Maloney AM; Weitzman S; Sung L
Cancer; 2007 Oct; 110(8):1832-9. PubMed ID: 17724682
[TBL] [Abstract][Full Text] [Related]
16. Fluid overload and acute kidney injury in children with tumor lysis syndrome.
Flood K; Rozmus J; Skippen P; Matsell DG; Mammen C
Pediatr Blood Cancer; 2021 Dec; 68(12):e29255. PubMed ID: 34302706
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia.
Xue Y; Chen J; Gao S; Zhai X; Wang N; Gao J; Lv Y; Yin M; Zhuang Y; Zhang H; Zhu X; Wu X; Li CK; Hu S; Liang C; Jin R; Jiang H; Yang M; Sun L; Pan K; Cai J; Tang J; Guan X; Fang Y
Sci Rep; 2021 May; 11(1):9656. PubMed ID: 33958615
[TBL] [Abstract][Full Text] [Related]
19. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
20. Prevention of tumor lysis syndrome using continuous veno-venous hemofiltration.
Saccente SL; Kohaut EC; Berkow RL
Pediatr Nephrol; 1995 Oct; 9(5):569-73. PubMed ID: 8580012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
